Delpacibart Braxlosiran FSHD Shows Promise in Disease Modification

Novartis has achieved a key clinical milestone with delpacibart braxlosiran FSHD, as its FORTITUDE biomarker cohort successfully met the primary endpoint by substantially suppressing DUX4-driven gene expression and reducing muscle damage markers in patients with facioscapulohumeral muscular dystrophy.

Delpacibart braxlosiran FSHD produced rapid, sustained declines in circulating KHDC1L and creatine kinase, confirming precise target engagement and decreased ongoing muscle injury. These results mirrored earlier dose-escalation data and validated the 2 mg/kg every-six-weeks regimen now advancing into the fully enrolled Phase III FORTITUDE-3 study.

Adaptive Design Bridges Molecular Action to Functional Gains

The randomized, placebo-controlled FORTITUDE trial used sequential cohorts to refine both dosing and biomarker strategy in 90 FSHD patients. By embedding 12-month biomarker evaluation into the 51-patient expansion cohort, researchers created a direct translational bridge between siRNA-mediated DUX4 suppression and downstream protection of muscle tissue, an approach that now informs the pivotal trial’s dual primary endpoints of quantitative muscle testing and 10-meter walk/run performance.

First-in-Class AOC Poised to Reshape Neuromuscular Care

With orphan designation and Fast Track status, delpacibart braxlosiran FSHD represents a potential first disease-modifying therapy for a condition affecting an estimated 45,000 to 87,000 people in the United States and European Union. The robust biomarker reductions supply compelling early evidence for regulators and payers while strengthening the overall value narrative for Novartis’ broader antibody-oligonucleotide conjugate platform across multiple rare neuromuscular disorders.

Novartis’ FORTITUDE trial results further bolster confidence that targeted DUX4 inhibition can translate into meaningful improvements in strength, mobility, and long-term independence for patients who currently have no approved treatment options.